Company Overview and News

 
Trading ideas: Axiata, Astro, United Malacca, Poh Huat

2018-09-27 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Axiata Group Bhd , Astro Malaysia Holdings Bhd, United Malacca Bhd and Poh Huat Resources Holdings Bhd to be among the stocks to watch on Thursday.
6888 6399 AXXTF 7088 2593

 
KLCI seen trending sideways, immediate support at 1,786

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI is expected to trend sideways today with immediate support at 1,786.
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
George Kent, Axiata, Astro, Bumi Armada, United Malacca, Poh Huat, MAHB, Apex Equity, Poh Kong, Hai-O and Eversendai

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
Poh Huat 3Q net profit dips on stiff competition, lower revenue in Vietnam

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Furniture maker Poh Huat Resources Holdings Bhd recorded a 4.72% decline in net profit for its third financial quarter ended July 31, 2018 (3QFY19) to RM9.2 million from RM9.66 million a year ago, as its Vietnamese operations faced stiffer competition and lower sales.
7088

 
Demand for Poh Huat’s furniture expected to remain strong

2018-07-31 theedgemarkets
Poh Huat Resources Holdings Bhd (July 30, RM1.46) Maintain buy with an unchanged target price of RM1.64: Strong demand for Poh Huat Resources Holdings Bhd’s furniture products would be underpinned by: 1) an improvement in consumer sentiment, 2) an increase in demand for furniture coming from countries like the US as economic growth strengthens, and 3) rising number of housing starts. On top of this, Poh Huat refreshes its product range to sustain its strong orders.
7088

 
Stock With Momentum: Poh Huat Resources Holdings Bhd

2018-07-24 theedgemarkets
Poh Huat Resources Holdings Bhd (-ve) TRADING of the shares in Poh Huat Resources Holdings Bhd (fundamental: 2.8/3, valuation: 1.8/3) triggered our momentum algorithm yesterday for the first time this year.
7088

 
Shares of furniture players gain on potential increase in demand amid US-China trade war

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): Interest in shares of export-oriented furniture manufacturers spiked, following news the United States is looking to impose a 10% tariff on more than 5,000 new Chinese imports worth US$200 billion, which includes furniture.
7006 7088 5101 LIIHF 5001

 
Poh Huat’s new Australia buy expected to contribute to future earnings

2018-07-19 theedgemarkets
Poh Huat Resources Holdings Bhd (July 18, RM1.30) Maintain buy with a target price (TP) of RM1.64: Poh Huat Resources Holdings Bhd announced that it had entered into a sales and purchase agreement with JSNJ Investment Pty Ltd, Australia, the owner and developer of a 3,212 square meter (sq m) detached warehouse cum office-showroom in Cranbourne West, Victoria, for a total consideration of A$4.95 million (RM14.
7088

 
KLCI to trend sideways, immediate hurdle at 1,748

2018-07-17 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI is seen trending sideways today with immediate hurdle at 1,748.
5843 5754 6084 7251 5072 4723 9083 MYPRY 5014 7088

 
Advancecon, Hiap Teck, Poh Huat, Velesto, Barakah Offshore, JAKS, Star, Utusan, Kumpulan Perangsang Selangor, MyEG, MAHB and Kumpulan Jetson

2018-07-17 theedgemarkets
KUALA LUMPUR (July 17): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (July 18) may include the following: Advancecon Holdings Bhd, Hiap Teck Venture Bhd, Poh Huat Resources Holdings Bhd, Velesto Energy Bhd, Barakah Offshore Petroleum Bhd, JAKS Resources Bhd, Star Media Group Bhd, Utusan Melayu (Malaysia) Bhd, Kumpulan Perangsang Selangor Bhd, My EG Services Bhd, Malaysia Airports Holdings Bhd and Kumpulan Jetson Bhd.
5843 5754 6084 7251 5072 4723 9083 MYPRY BSMAF 5014 7088 1818

 
Poh Huat buys second warehouse in Australia for property investment

2018-07-17 theedgemarkets
KUALA LUMPUR (July 17): Poh Huat Resources Holdings Bhd is buying a warehouse cum office showroom in Cranbourne West, Victoria, Australia for A$4.95 million.
BSMAF 7088 1818

 
Higher production costs seen to drag down Poh Huat earnings

2018-06-28 theedgemarkets
Poh Huat Resources Holdings Bhd (June 27, RM1.30) Maintain buy with a lower target price (TP) of RM1.64: Poh Huat Resources Holdings Bhd registered a slightly lower revenue by 1.3% year-on-year (y-o-y) of RM287.4 million for the first half ended April 30, 2018 (1HFY18), mainly attributable to lower sales from its Vietnamese operations, given the weaker Vietnam dong to the ringgit but partially offset by higher sales from the Malaysian operations due to continued strong demand for the panel-based bedroom sets for the US market and traditional office furniture.
7088

1
Trading ideas: Alam Maritim, Poh Huat, Hai-O, HLT Global, T7

2018-06-27 thestar.com.my
KUALA LUMPUR: Alam Maritim Resources Bhd , Poh Huat Resources Holdings Bhd , Hai-O Enterprise Bhd , HLT Global Bhd and T7 Global Bhd are among the stocks to watch, according to JF Apex Research.
5115 7668 7088

4
LSK aims to double sales by 2020 with MFO in its stable

2018-05-27 thestar.com.my
Lee Swee Kiat (LSK) Group Berhad managing director Eric Lee will the range of Napure Mattresses.
7006 BSMAF 7088 8079 LIIHF 1818

 
Disappointing Q1 results pull down Poh Huat shares

2018-03-21 thestar.com.my
PETALING JAYA: Shares of Poh Huat Resources Holdings Bhd fell to its lowest in two-and-a-half years after reporting disappointing results for its first quarter ended Jan 31, 2018, a day earlier.
7088

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...